Form 8-K - Current report:
SEC Accession No. 0001104659-25-045556
Filing Date
2025-05-07
Accepted
2025-05-07 16:16:31
Documents
15
Period of Report
2025-05-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2514212d1_8k.htm   iXBRL 8-K 24047
2 EXHIBIT 99.1 tm2514212d1_ex99-1.htm EX-99.1 95642
6 GRAPHIC tm2514212d1_ex99-1img01.jpg GRAPHIC 3656
  Complete submission text file 0001104659-25-045556.txt   310243

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA inva-20250507.xsd EX-101.SCH 3002
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE inva-20250507_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inva-20250507_pre.xml EX-101.PRE 22350
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2514212d1_8k_htm.xml XML 3682
Mailing Address 1350 OLD BAYSHORE HIGHWAY SUITE 400 BURLINGAME CA 94010
Business Address 1350 OLD BAYSHORE HIGHWAY SUITE 400 BURLINGAME CA 94010 6502389600
Innoviva, Inc. (Filer) CIK: 0001080014 (see all company filings)

EIN.: 943265960 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-30319 | Film No.: 25921630
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)